Key Points Clinical-stage biotech Evommune is seen as a potential buyout candidate. Its shares are up more than 55% so far this year. Its two pipeline candidates are making good progress in clinical trials. 10 stocks we like better than Evommune › Many clinical-stage biotech stocks have the potential to surge by more than 1,000% if they successfully make the transition to the commercial stage with...
Key Points Clinical-stage biotech Evommune is seen as a potential buyout candidate. Its shares are up more than 55% so far this year. Its two pipeline candidates are making good progress in clinical trials. 10 stocks we like better than Evommune › Many clinical-stage biotech stocks have the potential to surge by more than 1,000% if they successfully make the transition to the commercial stage with approved and well-received therapies. But small-cap biotechs are also among the riskiest stocks in the market. For every start-up that succeeds, there will be several similar companies that never make the leap to profitability, nor even get a therapy approved by the Food and Drug Administration. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Evommune (NYSE: EVMN) could become one of the winners, and its shares are up 54% so far this year. What is Evommune's edge? This small-cap biotech, which is focused on developing treatments for autoimmune conditions, went public this past November. Its primary candidate, EVO756, is a potential blockbuster. It's currently in a phase 2b trial testing it as a therapy for severe chronic spontaneous urticaria, a long-term autoimmune condition in which hives and deep tissue swelling can appear without an obvious trigger. Unlike other chronic spontaneous urticaria treatments, which aim to control histamine or IgE antibodies, EVO756 seeks to inhibit MRGPRX2, a kind of "volume knob" on mast cells. This prevents these cells from releasing the inflammatory chemicals that cause hives and swelling. EVO756 is also undergoing phase 2b clinical trials for the treatment of atopic dermatitis. Top-line results from the urticaria trial are expected in Q2, while results from the atopic dermatitis trial are expected in Q3 or Q4. Early data showed a clinical response in 93% of patients af...
A former Syrian colonel has appeared in a London court to face charges of crimes against humanity in the first prosecution of its kind in England and Wales. Salem Al-Salem is charged with murder and torture, crimes allegedly committed during the Syrian government’s violent crackdown on pro-democracy demonstrations in Damascus in 2011. Al-Salem, who fled to the UK, is alleged to have played a leadi...
A former Syrian colonel has appeared in a London court to face charges of crimes against humanity in the first prosecution of its kind in England and Wales. Salem Al-Salem is charged with murder and torture, crimes allegedly committed during the Syrian government’s violent crackdown on pro-democracy demonstrations in Damascus in 2011. Al-Salem, who fled to the UK, is alleged to have played a leading role in the violence at the start of the uprising against Bashar al-Assad, which led to a civil war and the eventual overthrow of Assad’s regime in 2024. The 58-year-old faces three counts of murder as a crime against humanity, three of torture and one of conduct ancillary to murder. The crimes are alleged to have happened while Al-Salem was serving as a colonel in the Syrian air force intelligence department, leading a group that attempted to quell demonstrations in Jobar, a village on the outskirts of Damascus. Al-Salem appeared at Westminster magistrates court via video link on Tuesday with a breathing tube over his mouth. The court was told he had motor neurone disease and was housebound. The chief magistrate, Paul Goldspring, agreed he did not need to give his name because of his health condition, but refused his lawyer’s request for reporting restrictions to protect his identity. “Naming the defendant would not lead to enhanced risk,” he said. The case marks the first time the Crown Prosecution Service (CPS) has brought charges of murder as a crime against humanity under the International Criminal Court Act 2001. A UK court convicted the Afghan warlord Faryadi Sarwar Zardad in 2005 of a “heinous” campaign of torture and hostage taking. The charges against Al-Salem relate to the murders of Omal Al-Homsi, Nizar Fayoumi-AlKhatib, Mohammed Salim Zahrak Balik and Talhat Dalal in April and July 2011. He is alleged to be responsible for killing three of the victims as part of a “widespread or systematic attack” against civilians. He also faces charges of torture against t...
The company will release earnings results for its third quarter, after the closing bell on Tuesday, March 10. Recent Price Cut & Analysts’ Expectations On Monday, Deutsche Bank analyst cut the price target from $375 to $300, Scotiabank analyst lowered the price target from $220 to $215 and Barclays analyst slashed the price target from $310 to $230. Overall, analysts expect Oracle to post third-qu...
The company will release earnings results for its third quarter, after the closing bell on Tuesday, March 10. Recent Price Cut & Analysts’ Expectations On Monday, Deutsche Bank analyst cut the price target from $375 to $300, Scotiabank analyst lowered the price target from $220 to $215 and Barclays analyst slashed the price target from $310 to $230. Overall, analysts expect Oracle to post third-quarter revenue of $16.9 billion, up from $14.13 billion in the same quarter last year, according to data from Benzinga Pro. Wall Street also anticipates earnings per share of $1.55, compared with $1.47 a year earlier. Section: Technical Analysis The stock is trading 1.2% below its 20-day simple moving average (SMA) and 25.2% below its 100-day SMA, indicating a challenging short-term outlook. Over the past 12 months, shares have increased by 1.21% and are currently positioned closer to their 52-week lows than highs, suggesting potential for recovery. Momentum Indicators The RSI is at 44.62, which is considered neutral territory, indicating a lack of strong momentum in either direction. Meanwhile, the MACD shows a value of -4.7484, with the signal line at -6.5837, suggesting a bullish crossover, which could indicate a potential upward shift. The combination of neutral RSI and a bullish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in price direction. Key Resistance : $165.50 : $165.50 Key Support: $138.50 Debt and Market Strategy Moreover, the broader context of Oracle’s financial health and market strategy was highlighted by high credit default swap levels due to its substantial debt, which exceeds $100 billion. This debt is largely attributed to its aggressive investments in AI technology. Steve Eisman commented on the situation, downplaying the risk of bankruptcy but expressing concerns over the opaque, highly leveraged credit deals in the tech sector. In the AI space, Oracle’s strategic decisions are part of a larger industry trend...
Images By Tang Ming Tung/DigitalVision via Getty Images OptimizeRx ( OPRX ) had a rough few months as the stock dropped from the $20s down to the single digits. A lot of the sell-off has to do with the AI-fear trade, which is probably overdone. OPRX stated that their business should have minimal disruption from AI . However, all may not be well with OPRX. The recent Q4 2025 earnings report provide...
Images By Tang Ming Tung/DigitalVision via Getty Images OptimizeRx ( OPRX ) had a rough few months as the stock dropped from the $20s down to the single digits. A lot of the sell-off has to do with the AI-fear trade, which is probably overdone. OPRX stated that their business should have minimal disruption from AI . However, all may not be well with OPRX. The recent Q4 2025 earnings report provides insights into why there was a sell-off reaction. The report shows some headwinds for the 2026 outlook. I have to admit, my previous call for a 'strong buy' has been an embarrassment, as the stock has sold off drastically since my last OPRX article was written . What I saw then was a low valuation and strong expected growth. While the valuation appeared low, it was deceiving due to the high amount of stock-based compensation that OPRX pays out. Plus, the growth looks stalled for 2026, which likely added to the selling. Insights From the Q4 2025 Earnings Report OptimizeRx's stock didn't sell off because of bad Q4 2025 results. The stock sold off because of cautious guidance for 2026, as possible headwinds could negatively impact the year. OPRX did experience some weakness as Q4 2025 revenue declined by 0.24% yoy to $32 million. However, this did beat analysts' estimates by $1.32 million. The better results were apparent on the company's bottom line. Non-GAAP EPS increased by an impressive 70% to $0.51, beating estimates by $0.29. The gross profit increased by 9% yoy to $24.1 million. Adjusted EBITDA increased 36% yoy to $12 million. OptimizeRx also achieved positive results for the full year in 2025. Revenue increased 19% yoy to a record $109.4 million. Adjusted EBITDA increased 108% yoy to $24.3 million. OPRX attributed its success to its largest and most established clients and to newer customers. The new growth came mostly from mid-tier and long-tail life science companies. While the Q4 and full-year 2025 results look positive, OPRX is experiencing softness in its year-t...
EU chief Ursula von der Leyen on Tuesday said Europe’s turn away from nuclear power had been a “strategic mistake”, as soaring oil prices rekindled concerns about the bloc’s energy vulnerability. Speaking at a nuclear summit in Paris, the European Commission president endorsed a return to atomic energy, saying the European Union would back investments in “innovative nuclear technologies”. “It was ...
EU chief Ursula von der Leyen on Tuesday said Europe’s turn away from nuclear power had been a “strategic mistake”, as soaring oil prices rekindled concerns about the bloc’s energy vulnerability. Speaking at a nuclear summit in Paris, the European Commission president endorsed a return to atomic energy, saying the European Union would back investments in “innovative nuclear technologies”. “It was a strategic mistake for Europe to turn its back on a reliable, affordable source of low-emission power,” she said. Advertisement The US-Israeli strikes on Iran and Tehran’s retaliatory attacks across the Gulf region have upended the world’s energy and transport sectors, virtually halting activity in the strategically vital Strait of Hormuz. EU officials have said the situation is yet to reach the crisis levels hit after Russia invaded Ukraine in 2022. 04:33 Fukushima 15 years on: why Japan’s younger generation is embracing nuclear power Fukushima 15 years on: why Japan’s younger generation is embracing nuclear power But the conflict has rekindled a debate on the bloc’s external dependencies and high energy costs, which European industry has long said hamper competitiveness vis-a-vis Asia and North America.
Tom Werner U.S. consumer spending surged to its highest level in three years during February, but the gains mask a deeper divide between wealthy and lower-income Americans, according to new data from the Bank of America Institute. Debit and credit card spending rose 3.2% year-over-year, with strength appearing across retail and services sectors. However, Liz Everett Krisberg, head of the Bank of A...
Tom Werner U.S. consumer spending surged to its highest level in three years during February, but the gains mask a deeper divide between wealthy and lower-income Americans, according to new data from the Bank of America Institute. Debit and credit card spending rose 3.2% year-over-year, with strength appearing across retail and services sectors. However, Liz Everett Krisberg, head of the Bank of America Institute, told CNBC that the growth reflects “an uneven resilience,” adding that “the K shape is continuing.” The “K-shaped” economy describes a recovery where higher-income households thrive while those at the bottom struggle. Krisberg explained that this divergence can be seen through two lenses: consumer spending patterns and wage growth trends. On the spending front, there is some encouraging news. Lower-income consumer spending nearly quadrupled from 0.3% in January to 1.1% in February, narrowing the gap with higher-income households to its smallest margin in six months. Lower-income households’ spending growth (Bank of America Institute internal data) “Everyone, higher, middle, lower, increased their spending,” Krisberg noted, though she emphasized the improvement was relative rather than absolute. The wage picture tells a more troubling story. Higher-income wages are accelerating above 4%, reaching their strongest level in nearly four years, while middle and lower-income wage growth has cooled by approximately 30 basis points. This has created the widest gap between higher and lower-income wage growth in at least a decade, dating back to the start of the Institute’s data series in 2015. Bank of America’s employment data also diverged from recent government reports showing an unexpected decline of 92,000 jobs. The Institute saw a 1.3% increase in households receiving income, a discrepancy Krisberg attributed to people potentially supplementing wages through gig work or multiple income sources. “Our numbers would tell you that it wasn’t as bad as what the BLS s...
In early March 2026, Apple rolled out a wave of lower-priced hardware, including the US$599 MacBook Neo, US$599 iPhone 17e, and refreshed iPad Air with M4, while also extending its ecosystem into areas like medical imaging and preparing a healthcare-focused presence at the HIMSS 2026 Global Health Conference. By pairing these budget-friendly devices and new professional tools with deeper Apple Int...
In early March 2026, Apple rolled out a wave of lower-priced hardware, including the US$599 MacBook Neo, US$599 iPhone 17e, and refreshed iPad Air with M4, while also extending its ecosystem into areas like medical imaging and preparing a healthcare-focused presence at the HIMSS 2026 Global Health Conference. By pairing these budget-friendly devices and new professional tools with deeper Apple Intelligence integration and expanding production into India and the U.S., Apple is working to widen its installed base while reinforcing its role in areas such as education, healthcare, and high-end computing. We’ll now examine how Apple’s push into budget-friendly, AI-enabled devices reshapes its investment narrative around ecosystem growth and services. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Apple Investment Narrative Recap To own Apple, you need to believe its massive device base, Services growth, and Apple Intelligence rollout can offset slowing hardware cycles and rising regulatory and geopolitical pressure. The latest push into US$599 AI‑ready devices and deeper healthcare ties is directionally consistent with that story, but it does not materially change the near term tug of war between AI‑driven upgrade optimism and margin risk from tariffs, regulation, and higher component costs. Among the recent announcements, the MacBook Neo stands out: Apple’s first US$599 MacBook, running A18 Pro with Apple Intelligence baked into macOS, sharply lowers the entry price for a “real” Mac. This directly connects to the key catalyst of growing the installed base to feed higher margin Services, while also testing how far Apple can push into budget tiers without sacrificing profitability at a time when memory costs and AI spending are ...
US Existing Home Sales Bounced In February As Mortgage Rates Tumbled Despite tumbling mortgage rates, existing home sales plunged (the most since COVID) in January , with some blaming 'below-normal temperatures' despite The West suffering the biggest declines (and unaffected by the winter storms). Consensus was for a modest 0.8% MoM decline in February (again despite an ongoing drop in mortgage ra...
US Existing Home Sales Bounced In February As Mortgage Rates Tumbled Despite tumbling mortgage rates, existing home sales plunged (the most since COVID) in January , with some blaming 'below-normal temperatures' despite The West suffering the biggest declines (and unaffected by the winter storms). Consensus was for a modest 0.8% MoM decline in February (again despite an ongoing drop in mortgage rates) but sales actually surprised to the upside, rising 1.7% MoM . Perhaps even more notably, January's 8.4% MoM plunge was revised up to a slightly less crazy 5.9% MoM drop ... Source: Bloomberg With the beat and upward revision, existing home sales were down just 1.45% YoY but SAAR topped 4mm (4.09mm) once again... Source: Bloomberg On the bright side, with mortgage rates at their lowest since 2022, existing home sales look set to continue to improve (unless Trump's war triggers more panic in rates)... Source: Bloomberg Mortgage rates fell at the end of last month to 6.09% after President Trump asked Fannie Mae and Freddie Mac to purchase $200 billion in mortgage-backed securities to help lower home-financing costs. The NAR’s monthly housing affordability gauge, which reflects changes in home prices, median income and borrowing costs, stands at the most-favorable reading since 2022. “Housing affordability is improving, and consumers are responding,” NAR Chief Economist Lawrence Yun said in a statement. “Still, there is a long way to go to return to pre-pandemic levels of transaction activity.” The NAR report showed the median selling price rose 0.3% from a year earlier — one of the smallest advances since the pandemic housing frenzy — to $398,000 last month. The inventory of previously owned homes increased 4.9% from a year ago to 1.29 million — the most for any February since 2020. Market analysts see home sales climbing this year, with estimates ranging from 1.7% to 14%, according to a survey by Bloomberg late last year. Tyler Durden Tue, 03/10/2026 - 10:09
Applied Materials, Inc. recently announced it is working with Micron Technology to co-develop next-generation DRAM, high-bandwidth memory and NAND for AI systems, leveraging Applied’s new US$5.00 billion EPIC Center in Silicon Valley and Micron’s Boise innovation hub to enhance energy-efficient, advanced packaging and memory architectures. This collaboration deepens Applied Materials’ role inside ...
Applied Materials, Inc. recently announced it is working with Micron Technology to co-develop next-generation DRAM, high-bandwidth memory and NAND for AI systems, leveraging Applied’s new US$5.00 billion EPIC Center in Silicon Valley and Micron’s Boise innovation hub to enhance energy-efficient, advanced packaging and memory architectures. This collaboration deepens Applied Materials’ role inside customers’ R&D roadmaps, potentially accelerating how quickly new AI-focused memory and packaging technologies move from lab concepts into large-scale manufacturing. We’ll now explore how Applied’s expanded co-development with Micron on advanced AI memory could reshape the company’s longer-term investment narrative. The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. Applied Materials Investment Narrative Recap To own Applied Materials, you need to believe that AI-driven demand for advanced chips and packaging will keep requiring more complex manufacturing tools, and that Applied can stay at the center of that tooling. The Micron co-development news directly reinforces the AI memory and advanced packaging catalyst in the near term, while also highlighting an ongoing risk: rising R&D intensity that may not always convert into timely, revenue-generating tools if customer adoption slows. The most closely linked recent announcement is Samsung joining Applied’s new US$5,000,000,000 EPIC Center, which, together with Micron’s participation, underlines how deeply Applied is embedding itself in leading-edge R&D for AI chips and memory. This kind of early co-innovation is central to the bullish catalyst that Applied can capture more process steps and higher value systems as AI architectures evolve, even as it faces export, competition and spending-cycle risks. Yet even as these AI partnerships deepen, investors should be aware that export controls and shifting global competition could...
Taiwan Semiconductor Manufacturing reported strong February revenue growth, but investors remain focused on seasonal weakness and potential energy disruptions.
Taiwan Semiconductor Manufacturing reported strong February revenue growth, but investors remain focused on seasonal weakness and potential energy disruptions.
Hailshadow/iStock via Getty Images Capricor Therapeutics ( CAPR ) added ~17% on Tuesday after the U.S. Food and Drug Administration agreed to review the company’s previously rejected lead candidate, Deramiocel, a cell therapy for patients with a rare disorder called Duchenne muscular dystrophy. In July 2025, Capricor ( CAPR ) shares dropped after the FDA issued a complete response letter, rejectin...
Hailshadow/iStock via Getty Images Capricor Therapeutics ( CAPR ) added ~17% on Tuesday after the U.S. Food and Drug Administration agreed to review the company’s previously rejected lead candidate, Deramiocel, a cell therapy for patients with a rare disorder called Duchenne muscular dystrophy. In July 2025, Capricor ( CAPR ) shares dropped after the FDA issued a complete response letter, rejecting its Biologics License Application for Deramiocel, targeted at cardiomyopathy in DMD patients. The regulator resumed the review with a target action date of August 22, 2026, after the company resubmitted the BLA with data from its HOPE-3 pivotal clinical trial, the San Diego, California-based biotech said. “We look forward to continuing to work closely with the FDA throughout the review process and remain focused on bringing this important therapy to patients as expeditiously as possible,” CEO Linda Marbán added. Capricor ( CAPR ) was among the notable gainers in biotech on Monday in reaction to the departure of Vinay Prasad, head of the FDA’s biologics unit. More on Capricor Therapeutics, Inc. Capricor Therapeutics: A High Risk/High Reward Name Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript Capricor: A Detailed Examination Of Hope-3 Biotech firm stocks rise on FDA vaccine head’s exit Seeking Alpha’s Quant Rating on Capricor Therapeutics, Inc.
District councillors representing Hong Kong’s outlying islands have opposed a plan to raise selected ferry fares by up to 12.8 per cent, arguing that it will discourage the elderly from travelling and harm the local economy. Members of the Islands District Council on Tuesday all raised concerns that another fare increase could be sought in response to soaring fuel prices. The remarks were made as ...
District councillors representing Hong Kong’s outlying islands have opposed a plan to raise selected ferry fares by up to 12.8 per cent, arguing that it will discourage the elderly from travelling and harm the local economy. Members of the Islands District Council on Tuesday all raised concerns that another fare increase could be sought in response to soaring fuel prices. The remarks were made as the Transport Department briefed council members on the fare adjustment proposal for six key ferry routes providing access to Cheung Chau, Lamma Island, Mui Wo and Peng Chau, among others. Advertisement Many district councillors emphasised the proposed increases could place a greater financial burden on elderly residents at a time when the city will overhaul its public transport subsidy scheme. Both are expected to take effect on April 1. The revamped subsidy scheme will no longer provide a flat fare of HK$2 for those aged 60 or above, and instead will offer concessions for trips priced up to HK$10 and an 80 per cent discount for rides costing over HK$10. Advertisement For example, an elderly person in Cheung Chau will have to pay HK$6.58 for a one-way high-speed ferry ride to Central between Mondays and Saturdays, and HK$9.52 on Sundays, once the policies take effect.